Proton Therapy in the Treatment of Liver Metastases

Status Recruiting

Clinical Trial Summary

Local control of hepatic metastases appears to be a major determinant of overall survival. However, many patients are not suitable for resection due to medical or surgical reasons. Therefore, there is an important role for a treatment that can provide the equivalent of tumor resection with minimal morbidity. Stereotactic body radiotherapy (SBRT) delivers an ablative regimen of highly focused external beam radiotherapy that targets one or more discrete extracranial lesions. Published reports using SBRT to treat liver metastases have shown actuarial local control rates ranging from 50-100% with higher doses associated with better local control. In patients with metastatic liver disease, aggressive local therapy using modern radiotherapy techniques are promising and project to have a substantial role in the treatment of metastatic liver cancer to treat unresectable disease. The dosimetric advantage of proton therapy may lead to improved clinical outcomes with less morbidity, however, there is no clinical data to confirm this assertion. We thus propose a phase I study to determine the feasibility and safety of stereotactic body proton therapy in patients with liver metastases followed by a phase II study to determine the efficacy of such treatment on local control.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01697371
Study type	Interventional
Source	Loma Linda University
Contact	Proton Referral Office First Call: Referral Office intake person
Phone	909-558-4288 or 1 800 PROTONS
Status	Recruiting
Phase	N/A
Start date	August 22, 2012
Completion date	September 2033

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03781934` - A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations	Phase 1/Phase 2
Completed	`NCT02107755` - Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma	Phase 2
Recruiting	`NCT05057052` - Cryoablation Combined With Sintilimab Plus Regorafenib In Previously Treated Colorectal Cancer Liver Metastasis	Phase 2
Recruiting	`NCT06120127` - Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence	Phase 2
Recruiting	`NCT04837885` - Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases	Phase 2
Terminated	`NCT04589884` - Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment
Not yet recruiting	`NCT04520737` - Multimodal Prehabilitation During Chemotherapy in Patients With Colorectal Liver Metastases	N/A
Terminated	`NCT02465112` - Metabolic Radiotherapy After Complete Resection of Liver Metastases in Patient With Digestive Neuroendocrine Tumor	Phase 3
Completed	`NCT02352259` - Treatment of Liver Metastases With Electrochemotherapy (ECTJ) Phase II	Phase 2
Active, not recruiting	`NCT01763450` - Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer	Phase 2
Withdrawn	`NCT01631539` - Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC	N/A
Recruiting	`NCT01250158` - Liver-PILP First-in-Man	N/A
Terminated	`NCT01233544` - Radiofrequency Ablation Versus Stereotactic Radiotherapy in Colorectal Liver Metastases	Phase 3
Completed	`NCT01347333` - Stereotactic Body Radiotherapy for Liver Tumors	N/A
Completed	`NCT00587756` - Alternative to Two-Stage Hepatectomy	N/A
Completed	`NCT01683357` - Prognosis of One-stage Hepatectomy for Bilobar Colorectal Metastases	N/A
Completed	`NCT04942665` - Low Dose ICG for Biliary Tract and Tumor Imaging	Phase 2
Not yet recruiting	`NCT05354674` - Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis
Recruiting	`NCT04616495` - Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases
Not yet recruiting	`NCT04509635` - Cetuximab Re-challenge for Colorectal Cancer Liver Metastasis	Phase 3